Category Press Releases

Cullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025

Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S. affiliate Taiho Oncology, Inc., has announced encouraging new results from…

Read MoreCullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025

Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment

Lilly’s Kisunla (Donanemab) Gains Marketing Authorization in Australia for Early Alzheimer’s Treatment Eli Lilly and Company has announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), a novel treatment for early symptomatic Alzheimer’s disease.…

Read MoreLilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment

Merck and imec Partner to Advance Next-Generation Microphysiological Systems Platform

Merck and imec Forge Strategic Alliance to Revolutionize Drug Discovery Through Advanced Microphysiological Systems Merck, a global leader in science and technology, and imec, a premier international hub for research and innovation in nanoelectronics and digital technologies, have announced a…

Read MoreMerck and imec Partner to Advance Next-Generation Microphysiological Systems Platform